Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Company Overview - Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, utilizing anti-FcRn technology to create targeted treatments [3]. Financial Results Announcement - Immunovant will report its financial results for the third quarter ending December 31, 2025, and provide a business update on February 6, 2026, at 8:00 a.m. ET [1]. Conference Call Access - Investors can access the conference call by registering online, with details available on Immunovant's website under the "News & Events" section [2].